Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:52:13.287Z.
Calculation as of: 2026-10-06T21:52:13.287Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4147f1633fe526555426f89ecb5945f37dfc8ef4561f7e6db8f1148c00751c21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Kodiak Sciences Inc.
Market Cap
$5.78B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.79B
Operating Cash Flow Yield
N/A
TTM Avg
100.19%
3Y Avg
100.19%
5Y Avg
100.19%
Market Cap
$5.87B
Operating Cash Flow Yield
3.15%
TTM Avg
3.25%
3Y Avg
2.26%
5Y Avg
2.35%
Market Cap
$5.95B
Operating Cash Flow Yield
2.21%
TTM Avg
1.51%
3Y Avg
3.26%
5Y Avg
5.50%
Market Cap
$5.53B
Operating Cash Flow Yield
5.74%
TTM Avg
5.92%
3Y Avg
6.07%
5Y Avg
8.26%
Market Cap
$5.52B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.23B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | N/A | 100.19% | 100.19% | 100.19% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 3.15% | 3.25% | 2.26% | 2.35% |
| GRAIL Inc. (GRAL)vs › | $5.89B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 2.21% | 1.51% | 3.26% | 5.50% |
| RadNet, Inc. (RDNT)vs › | $5.53B | 5.74% | 5.92% | 6.07% | 8.26% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | N/A | N/A | N/A | N/A |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | 13.90% | 13.90% | 13.90% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
